Menu
1 min read · estimated
APPROVED USE
What FDA approved
As a single agent for adults with locally recurrent or metastatic anal canal squamous cell carcinoma whose disease progressed on platinum-based chemotherapy or who could not tolerate it.
LAMPGEN ANALYSIS
Why it matters
The monotherapy label addresses a post-platinum or platinum-intolerant population distinct from the first-line combination.
What research teams should watch
Capture whether treatment stopped because of progression or intolerance, and use the appropriate criterion during prescreening.
PRIMARY RECORDS